- Home
- AMLX vs DAWN Comparison
AMLX vs DAWN Comparison
Compare AMLX & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- DAWN
- Stock Information
- Founded
- AMLX 2014
- DAWN 2018
- Country
- AMLX United States
- DAWN United States
- Employees
- AMLX N/A
- DAWN N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- AMLX Health Care
- DAWN Health Care
- Exchange
- AMLX Nasdaq
- DAWN Nasdaq
- Market Cap
- AMLX 749.9M
- DAWN 624.8M
- IPO Year
- AMLX 2022
- DAWN 2021
- Fundamental
- Price
- AMLX $12.77
- DAWN $6.99
- Analyst Decision
- AMLX Strong Buy
- DAWN Strong Buy
- Analyst Count
- AMLX 7
- DAWN 7
- Target Price
- AMLX $14.86
- DAWN $27.86
- AVG Volume (30 Days)
- AMLX 2.0M
- DAWN 922.7K
- Earning Date
- AMLX 11-06-2025
- DAWN 10-29-2025
- Dividend Yield
- AMLX N/A
- DAWN N/A
- EPS Growth
- AMLX N/A
- DAWN N/A
- EPS
- AMLX N/A
- DAWN N/A
- Revenue
- AMLX N/A
- DAWN $187,638,000.00
- Revenue This Year
- AMLX N/A
- DAWN $12.56
- Revenue Next Year
- AMLX N/A
- DAWN $48.02
- P/E Ratio
- AMLX N/A
- DAWN N/A
- Revenue Growth
- AMLX N/A
- DAWN 2190.50
- 52 Week Low
- AMLX $2.60
- DAWN $5.64
- 52 Week High
- AMLX $13.07
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- AMLX 82.10
- DAWN 46.39
- Support Level
- AMLX $11.42
- DAWN $6.90
- Resistance Level
- AMLX $12.25
- DAWN $7.58
- Average True Range (ATR)
- AMLX 0.59
- DAWN 0.26
- MACD
- AMLX 0.21
- DAWN -0.07
- Stochastic Oscillator
- AMLX 91.70
- DAWN 10.78
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.